Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 314Carcinoma, Non-Small-Cell Lung 162Breast Neoplasms 125Neoplasm Metastasis 106Melanoma 95Leukemia, Myeloid, Acute 80Lymphoma 79Multiple Myeloma 74Colorectal Neoplasms 73Ovarian Neoplasms 70Lymphoma, Non-Hodgkin 63Recurrence 58Prostatic Neoplasms 56Pancreatic Neoplasms 51Lung Neoplasms 50Carcinoma, Renal Cell 40Glioblastoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Advanced Solid Tumors 37Leukemia 36Myelodysplastic Syndromes 35Triple Negative Breast Neoplasms 34Head and Neck Neoplasms 33Sarcoma 31Brain Neoplasms 31Urinary Bladder Neoplasms 30Stomach Neoplasms 30Lymphoma, Follicular 28

Interventions

ublituximab 1LFB-R603 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has results × Myelitis, Transverse × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡